CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 181 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2024. The put-call ratio across all filers is 2.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,565,025 | +119.4% | 96,326 | +148.8% | 0.00% | 0.0% |
| Q1 2024 | $1,624,617 | +17.5% | 38,709 | +11.0% | 0.00% | 0.0% |
| Q4 2023 | $1,382,865 | +44.1% | 34,868 | 0.0% | 0.00% | – |
| Q3 2023 | $959,567 | -16.0% | 34,868 | +9.8% | 0.00% | -100.0% |
| Q2 2023 | $1,142,293 | 0.0% | 31,748 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,142,293 | -15.3% | 31,748 | +5.0% | 0.00% | 0.0% |
| Q4 2022 | $1,347,887 | -99.8% | 30,242 | 0.0% | 0.00% | – |
| Q3 2022 | $850,103,000 | +7.1% | 30,242 | +2.7% | 0.00% | – |
| Q2 2022 | $793,675,000 | -29.6% | 29,439 | -11.0% | 0.00% | – |
| Q1 2022 | $1,127,012,000 | -11.9% | 33,089 | 0.0% | 0.00% | – |
| Q4 2021 | $1,278,559,000 | -34.6% | 33,089 | -8.6% | 0.00% | -100.0% |
| Q3 2021 | $1,954,978,000 | +71.9% | 36,210 | +6.5% | 0.00% | – |
| Q2 2021 | $1,137,361,000 | +56.1% | 34,012 | -3.9% | 0.00% | – |
| Q1 2021 | $728,766,000 | +22.4% | 35,377 | +4.1% | 0.00% | – |
| Q4 2020 | $595,452,000 | – | 33,987 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,388,967 | $125,425,669 | 9.68% |
| 5AM Venture Management, LLC | 497,270 | $18,403,963 | 4.12% |
| COMMODORE CAPITAL LP | 1,425,000 | $52,739,250 | 3.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 374,910 | $13,875,419 | 3.27% |
| TSP Capital Management Group, LLC | 249,220 | $9,223,635 | 2.89% |
| Eventide Asset Management | 3,327,132 | $123,137,155 | 2.11% |
| Affinity Asset Advisors, LLC | 475,400 | $17,594,554 | 2.03% |
| Novo Holdings A/S | 850,000 | $31,458,500 | 1.83% |
| Bellevue Group AG | 2,971,615 | $109,979,471 | 1.79% |
| Redmile Group, LLC | 718,723 | $26,599,938 | 1.61% |